FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

Jul 28, 201700:06:00Health

FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017

Related Episodes

Continue listening to more episodes from FDA Drug Information Updates.

Jul 31, 2018 - 00:24:45

The FDA has made strides in improving transparency and data access, and has implemented tools to allow th...

May 4, 2018 - 00:02:59

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures a...

Jan 7, 2018 - 00:08:29

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the...

Jan 5, 2018 - 00:02:59

The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-b...

Jan 4, 2018 - 00:03:00

The FDA announced that a review of four large clinical safety trials shows that treating asthma with long...

Oct 29, 2017 - 00:09:22

Many listeners may be familiar with the FDA's Adverse Event Reporting System or FAERS. Data in FAERS supp...

Aug 17, 2017 - 00:05:29

FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complicatio...

Jul 25, 2017 - 00:09:00

FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small...